News
WASHINGTON, DC – Dr. Vinay Prasad has been reinstated to a senior position at the Food and Drug Administration, according to ...
With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial ...
Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...
In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...
Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...
1d
Asianet Newsable on MSNTrump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping IsaacmanPrasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced ...
1d
TipRanks on MSNSarepta price target raised to $14 from $12 at CitiCiti raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company’s Q2 sales beat estimates ...
The July CPI is expected to show a rise in annual retail inflation. AMC and Cisco among those reporting earnings. Nvidia ...
Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...
Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results